查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018815

自體免疫疾病體外診斷與實驗室自建檢測市場：2026年至2032年全球市場預測（按檢測類型、技術、產品類型、檢體類型、最終用戶和應用分類）

IVD & LDT For Autoimmune Diseases Market by Test Type, Technology, Product Type, Sample Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，自體免疫疾病的體外診斷和實驗室自建市場價值將達到 192.6 億美元，到 2026 年將成長至 202.8 億美元，到 2032 年將達到 275.6 億美元，年複合成長率為 5.25%。

主要市場統計數據
基準年 2025 192.6億美元
預計年份：2026年 202.8億美元
預測年份 2032 275.6億美元
複合年成長率 (%) 5.25%

對當前自體免疫疾病診斷現狀進行簡要概述，重點關注診斷方法的創新、臨床應用的促進因素以及對相關人員的戰略意義。

診斷技術的創新、不斷演進的臨床路徑以及臨床醫生對自體免疫疾病檢測準確性日益成長的需求，共同為診斷和檢測服務領域的相關人員創造了一個關鍵的轉折點。本執行摘要概述了檢測平台、臨床醫生採納模式以及體外診斷與實驗室自建檢測 (LDT) 之間相互作用的最新趨勢，這些因素共同塑造了診斷工作流程和患者護理過程。報告重點關注技術選擇、監管政策調整和檢查室運作模式如何影響檢測方法的選擇、分析性能以及後續的護理協調。

檢測技術創新、監管趨勢和臨床工作流程現代化的整合正在重塑自體免疫疾病的診斷，並加速跨部門合作。

近年來，變革性的變化從根本上改變了自體免疫疾病診斷的開發、檢驗和臨床應用方式。檢測化學和平台整合技術的進步提高了分析精度，多重檢測能力使得從單一檢體中獲得更廣泛的免疫譜分析成為可能。同時，檢查室正在採用自動化和數位化連接來簡化工作流程並支援高通量檢測，這反過來又影響了報告時間和檢測能力管理。

本研究評估了 2025 年關稅調整對診斷供應鏈、籌資策略和區域製造決策的累積營運影響。

2025年實施的關稅政策調整及相關貿易措施為全球診斷試劑和儀器組件供應鏈帶來了新的波動。這些關稅趨勢增加了製造商和檢查室的採購複雜性，促使他們重新評估籌資策略、庫存管理和供應商多元化。為此，許多相關人員探索了近岸外包方案和建立替代供應商關係，以減輕進口成本波動和前置作業時間不確定性的影響。

詳細的細分分析揭示了測試類型、檢測技術、產品類型、最終用戶、臨床應用和檢體方式如何影響策略選擇。

細分分析揭示了不同檢測類型、技術、產品類型、最終用戶、應用和檢體類型之間的不同趨勢，這些趨勢影響著臨床效用、採購選擇和開發重點。按檢測類型分類，這些趨勢包括抗環瓜氨酸肽抗體、抗核抗體、乳糜瀉和類風濕因子，每種檢測都有其獨特的分析要求和臨床醫生對特異性和可解釋性的期望。由於抗環瓜氨酸肽抗體 (ACCP) 檢測具有有用的預後分析特性，因此通常是類風濕性關節炎早期診斷的首選方法。另一方面，抗核抗體 (ANA) 檢測通常用作篩檢工具，需要反射性演算法來指導後續檢測。乳糜瀉的血清學檢測需要與病歷和基因檢測途徑密切配合，而類風濕因子檢測作為更廣泛的發炎性疾病評估的一部分仍然具有重要價值。

關鍵地區不同的法規環境、支付方框架和臨床基礎設施如何決定診斷測試部署模式和策略市場進入？

區域趨勢以獨特的方式影響技術採納模式、監管路徑和商業性模式。在美洲，醫療保健系統涵蓋了高度集中的國家級計畫和公私混合模式，支付方的影響力顯著影響報銷路徑和技術採納率。關鍵市場的臨床實踐指南和專家網路推動了臨床醫生對特定自體免疫檢測的需求，而大學附屬醫院通常主導轉化檢驗，從而指南更廣泛的臨床應用。因此，與當地指南制定和支付方證據要求一致的推廣策略往往能夠加速技術採納。

針對公司和檢查室的策略方法，強調平台擴展、建立證據夥伴關係和業務規模化，以促進診斷可靠性和臨床整合。

自體免疫診斷領域的企業策略體現了多元化的優先事項，包括平台創新、夥伴關係以及服務拓展，以滿足臨床需求和檢查室偏好。主要企業正致力於擴展檢測項目並提昇平台間的互通性，以滿足檢體檢查室和高通量參考中心的需求。這些努力通常與和學術機構的策略合作相結合，以檢驗新型生物標記，並產生納入指南和獲得支付方審核所需的臨床證據。

為診斷和實驗室領導者提供可操作的策略重點，以加強證據、增強韌性並加快所有護理路徑中的臨床實施。

行業領導者應採取協作策略，協調檢測開發、證據生成和檢查室運營，以加速臨床應用並改善患者預後。首先，應優先進行臨床檢驗項目，以證明其在真實患者群體中具有實際效用，並確保研究設計能夠反映臨床醫生的決策要點和支付方的證據要求。同時，應投資於互通性和工作流程整合，確保檢測能夠無縫整合到實驗室資訊系統和電子健康記錄中，從而最大限度地減輕申請檢測的臨床醫生和檢查室工作人員的負擔。

透過透明、多方面的調查方法，結合專家訪談、指南整合和可複製的分析框架，我們得出實用的診斷見解。

本研究整合了多種資料來源、結構化訪談和透明的分析框架，以確保得出可靠且可重複的結論。關鍵的定性資料包括對臨床實驗室管理人員、檢測開發人員、監管專家和自體免疫疾病臨床醫生的訪談，這些訪談提供了關於檢驗實踐、推廣障礙以及影響臨床決策因素的實用見解。這些訪談構成了主題分析的基礎，並指導了案例研究的選擇，這些案例研究展示了檢測方法在診斷過程中的實際應用。

結論：透過協調創新、證據生成和運作韌性，推動自體免疫疾病診斷的實質改善。

最後，自體免疫疾病診斷領域正處於一個轉折點，其特點是分析性能要求不斷提高、證據生成與臨床效用之間的聯繫日益緊密，以及受供應鏈現實驅動的更為嚴格的運營審查。整合嚴格檢驗、無縫工作流程相容性和穩健籌資策略的相關人員將更有能力將技術進步轉化為實際的臨床影響。體外診斷和實驗室自建檢測方法之間的互動提供了兩個切實可行的途徑，使標準化和靈活性能夠並存，從而滿足多樣化的臨床需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：自體免疫疾病體外診斷與實驗室自建市場－依檢測類型分類

  • 抗環瓜氨酸肽
  • 抗核抗體
  • 乳糜瀉
  • 類風濕因子

第9章：自體免疫疾病體外診斷與實驗室自建市場：依技術分類

  • 化學冷光免疫檢測
  • 酵素免疫分析法
  • 螢光免疫分析
  • 多重免疫檢測

第10章：自體免疫疾病體外診斷與實驗室自建市場：依產品類型分類

  • 體外診斷試劑
  • 實驗室開發的測試

第11章自體免疫疾病的體外診斷與實驗室自建市場—檢體類型

  • 乾血斑
  • 電漿
  • 血清
  • 全血

第12章：自體免疫疾病的體外診斷和實驗室自建市場：按最終用戶分類

  • 學術研究機構
  • 診斷檢查室
  • 醫院檢查室
  • 標準檢驗組織

第13章：自體免疫疾病的體外診斷與實驗室自建市場：按應用領域分類

  • 乳糜瀉
  • 多發性硬化症
  • 類風濕性關節炎
  • 全身性紅斑性狼瘡
  • 1型糖尿病

第14章：自體免疫疾病體外診斷與實驗室自建市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：自體免疫疾病體外診斷與實驗室自建市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：自體免疫疾病體外診斷與實驗室自建市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國自體免疫疾病的體外診斷與實驗室自建市場

第18章：中國自體免疫疾病體外診斷與實驗室自建市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies Inc.
  • Atlas Link Technology Co., Ltd
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioMerieux SA
  • Corgenix, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • EUROIMMUN AG
  • F. Hoffmann-La Roche Ltd.
  • Grifols, SA
  • Hologic Inc.
  • ImmunoScience India Pvt. Ltd.
  • Ortho Clinical Diagnostics, Inc.
  • PerkinElmer, Inc.
  • Quest Diagnostics, Inc.
  • Quidel Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc
Product Code: MRR-ED54C46E8807

The IVD & LDT For Autoimmune Diseases Market was valued at USD 19.26 billion in 2025 and is projected to grow to USD 20.28 billion in 2026, with a CAGR of 5.25%, reaching USD 27.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.26 billion
Estimated Year [2026] USD 20.28 billion
Forecast Year [2032] USD 27.56 billion
CAGR (%) 5.25%

A concise orientation to the current autoimmune diagnostics environment highlighting assay innovation, clinical adoption drivers, and strategic implications for stakeholders

The convergence of diagnostic innovation, evolving clinical pathways, and growing clinician demand for precision in autoimmune disease detection has created a pivotal moment for stakeholders across diagnostics and laboratory services. This executive summary distills recent advances in assay platforms, clinician adoption patterns, and the interplay between in vitro diagnostics and lab-developed tests that together shape diagnostic workflows and patient journeys. It centers on how technological choices, regulatory clarity, and laboratory operational models influence test selection, analytical performance, and downstream care coordination.

As diagnostics teams and laboratory leaders evaluate next-generation assay adoption, they must balance analytical sensitivity and specificity with workflow integration and reimbursement realities. Laboratory directors increasingly prioritize assays that reduce turnaround time while preserving clinical confidence, and clinicians seek tests that support earlier, more definitive diagnoses. Meanwhile, manufacturers refine product portfolios to address unmet needs in serology and biomarker detection, and academic centers expand translational programs to validate novel targets.

Taken together, these dynamics underscore the importance of aligning product development, clinical validation, and commercialization strategies. This summary outlines the strategic considerations that leaders should weigh when designing evidence generation plans, optimizing laboratory operations, and engaging payers and clinicians to improve diagnostic impact and patient outcomes.

How converging assay innovations, regulatory dynamics, and clinical workflow modernization are reshaping autoimmune diagnostics and accelerating cross-sector collaboration

Recent transformative shifts have altered how autoimmune disease diagnostics are developed, validated, and adopted across clinical settings. Advances in assay chemistries and platform integration have improved analytical precision, while multiplexing capabilities enable broader immunoprofiling from single samples. In parallel, laboratories are embracing automation and digital connectivity to streamline workflows and support high-throughput testing, which in turn affects turnaround times and capacity management.

Regulatory and reimbursement landscapes have also evolved, prompting manufacturers and laboratories to accelerate robust clinical validation and real-world evidence generation. These trends favor tests that demonstrate actionable clinical utility and that fit into clinicians' decision-making pathways. The rise of lab-developed tests alongside commercial in vitro diagnostics has created a complementary ecosystem: LDTs often address niche or emergent clinical needs quickly, while commercial IVDs prioritize standardization and scalability. Consequently, strategic partnerships between clinical laboratories, academic research centers, and commercial manufacturers have grown more common, facilitating faster translation of biomarkers into validated testing options.

Furthermore, patient-centric care models and increased clinician awareness of autoimmune heterogeneity emphasize the need for more precise diagnostic algorithms. As a result, stakeholders are investing in clinician education, multidisciplinary diagnostic protocols, and integrated reporting that links serologic results to clinical phenotypes. Overall, these shifts are driving a more collaborative, data-driven approach to autoimmune diagnostics, where technological capability, evidence generation, and operational readiness intersect to determine clinical adoption.

Assessing the cumulative operational consequences of 2025 tariff adjustments on diagnostic supply chains, sourcing strategies, and regional manufacturing decisions

Tariff policy adjustments and related trade measures introduced in 2025 have introduced new variables into global supply chains for diagnostic reagents and instrument components. These tariff developments increased procurement complexity for manufacturers and laboratories, prompting reassessments of sourcing strategies, inventory management, and supplier diversification. In response, many stakeholders examined nearshoring options and alternative supplier relationships to mitigate exposure to variable import costs and lead-time uncertainties.

Supply chain reactions to tariff changes encouraged manufacturers to revisit bill-of-materials strategies and to prioritize modular instrument designs that allow substitution of nonproprietary parts. Simultaneously, diagnostic laboratories adjusted procurement windows, increasing buffer inventories for critical consumables and negotiating longer-term agreements with domestic or regional distributors when feasible. These operational shifts, while preserving testing continuity, placed a premium on supply chain visibility and proactive supplier risk assessments.

Moreover, the tariff environment catalyzed strategic conversations about manufacturing footprint and regional capacity. Some firms accelerated investments in regional manufacturing and final assembly capabilities to reduce cross-border exposure, while others amplified their focus on validating multiple reagent suppliers to ensure continuity. Collectively, these adaptations underscore the critical link between trade policy and diagnostic program resilience, highlighting the need for scenario planning and agile procurement practices to sustain testing access and laboratory operations.

Detailed segmentation insights revealing how test types, assay technologies, product categories, end users, clinical applications, and sample modalities influence strategic choices

Segmentation analysis reveals differentiated dynamics across test types, technologies, product categories, end users, applications, and sample types that influence clinical utility, procurement choices, and development priorities. Based on Test Type, the landscape includes Anti Cyclic Citrullinated Peptide, Antinuclear Antibody, Celiac Disease, and Rheumatoid Factor, each presenting unique analytical requirements and clinician expectations for specificity and interpretability. Anti Cyclic Citrullinated Peptide assays are commonly prioritized for early rheumatoid arthritis diagnosis because their analytical characteristics support prognostic use, whereas Antinuclear Antibody testing often serves as a screening tool requiring reflex algorithms to guide follow-up testing. Celiac Disease serology necessitates tight integration with clinical history and genetic testing pathways, and Rheumatoid Factor testing retains value as part of broader inflammatory workups.

Based on Technology, stakeholders evaluate platforms including Chemiluminescence Immunoassay, Enzyme Linked Immunosorbent Assay, Fluorescence Immunoassay, and Multiplex Immunoassay when balancing throughput, sensitivity, and cost. Chemiluminescence Immunoassay platforms often appeal to high-volume laboratories seeking automated workflows and consistent performance, while Enzyme Linked Immunosorbent Assay remains a flexible option for lower throughput and centralized reference testing. Fluorescence Immunoassay can offer enhanced sensitivity for specific analytes, and Multiplex Immunoassay enables simultaneous profiling that supports differential diagnosis and research-grade immunophenotyping.

Based on Product Type, distinctions between In Vitro Diagnostic and Lab Developed Test pathways shape validation rigor, regulatory interaction, and commercial strategy. In Vitro Diagnostic solutions emphasize standardized kits and instrument integration to facilitate broad adoption, whereas Lab Developed Tests provide customization and rapid responsiveness to evolving clinical needs, especially in specialized centers. Based on End User, academic and research institutes, diagnostic laboratories, hospital laboratories, and reference laboratories each maintain different priorities related to validation depth, throughput, clinical integration, and payer relationships; academic centers drive translational validation, hospital laboratories focus on clinician alignment and rapid turnaround, and reference laboratories emphasize scale and centralized expertise.

Based on Application, reporting for Celiac Disease, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Type 1 Diabetes demands tailored panels and interpretive frameworks that reflect disease-specific biomarker signatures and clinical algorithms. Clinicians increasingly expect tests to provide context-rich reports that integrate serologic patterns with likelihood assessments and recommended next steps. Finally, based on Sample Type, modalities such as Dried Blood Spot, Plasma, Serum, and Whole Blood affect collection logistics, stability considerations, and suitability for decentralized testing or remote sampling programs. Dried Blood Spot sampling supports outreach and decentralized screening initiatives, while plasma and serum remain predominant for high-sensitivity assays performed in centralized laboratories. These segmentation insights collectively inform product development priorities, clinical validation strategies, and commercialization approaches across the diagnostic ecosystem.

How distinct regulatory environments, payer frameworks, and clinical infrastructures across major regions determine diagnostic adoption patterns and strategic market entry

Regional dynamics shape adoption patterns, regulatory pathways, and commercial approaches in distinctive ways. Across the Americas, health systems vary from highly centralized national programs to mixed public-private models, and payer influence strongly shapes test reimbursement pathways and adoption velocity. Clinical practice guidelines and specialist networks in major markets drive clinician demand for specific autoimmune assays, and academic medical centers often lead translational validation that informs broader clinical adoption. Consequently, engagement strategies that align with local guideline development and payer evidence requirements tend to facilitate uptake.

In Europe, Middle East & Africa, the regulatory environment is heterogeneous, with some regions emphasizing centralized regulatory reviews and others maintaining national approval pathways. This diversity encourages modular regulatory and market entry strategies, alongside targeted clinical studies that address country-specific clinical practice patterns. Additionally, public health priorities and variable laboratory infrastructure across the region influence the feasibility of decentralized testing and the adoption of automated platforms versus reference lab models. Manufacturers and laboratories therefore balance regional evidence generation with flexible distribution partnerships.

Asia-Pacific markets demonstrate rapid uptake of innovative diagnostic technologies, supported by investments in clinical research infrastructures and expanding private laboratory networks. Diverse healthcare financing models and large patient populations create opportunities for both centralized reference testing and point-of-care initiatives, particularly when supported by remote-sampling approaches like Dried Blood Spot. Overall, regional strategies must account for regulatory complexity, payer frameworks, and local clinical practice to optimize adoption and align evidence generation with stakeholder expectations.

Strategic corporate and laboratory approaches highlighting platform expansion, evidence partnerships, and operational scaling that drive diagnostic credibility and clinical integration

Company strategies in autoimmune diagnostics reflect divergent priorities including platform innovation, partnerships, and service expansion to capture clinical demand and laboratory preference. Leading assay developers focus on expanding assay menus and enhancing platform interoperability to meet the needs of hospital laboratories and high-volume reference centers. These efforts often pair with strategic collaborations with academic institutions to validate novel biomarkers and to generate the clinical evidence necessary for guideline inclusion and payer consideration.

Laboratory groups and diagnostics service providers invest in expanding their LDT capabilities and in establishing centers of excellence for autoimmune testing, enabling rapid deployment of new assays and supporting clinician education. At the same time, developers of multiplex technologies emphasize the value proposition of comprehensive immunoprofiling for complex autoimmune presentations, targeting neurology and rheumatology centers that require broader serologic views for differential diagnosis. Mergers, acquisitions, and co-development agreements increasingly serve as mechanisms to accelerate entry into adjacent clinical segments and to access distribution networks in key regions.

Across commercial and laboratory stakeholders, there is a shared emphasis on evidence generation, interoperability, and scalable operations. Consequently, corporate investments prioritize clinical validation studies, real-world evidence programs, and post-market surveillance that demonstrate test performance in diverse patient cohorts. This focus enables companies and laboratories to align product positioning with clinician needs, regulatory expectations, and payer requirements, reinforcing diagnostic credibility and facilitating integration into care pathways.

Actionable strategic priorities for diagnostics and laboratory leaders to strengthen evidence, enhance resilience, and accelerate clinical adoption across care pathways

Industry leaders should adopt coordinated strategies that align assay development, evidence generation, and laboratory operations to accelerate clinical adoption and improve patient outcomes. First, prioritize clinical validation programs that demonstrate actionable utility in real-world patient cohorts, ensuring that study designs reflect clinician decision points and payer evidence needs. Simultaneously, invest in interoperability and workflow integration so that assays fit seamlessly into laboratory information systems and electronic health records, thereby minimizing friction for ordering clinicians and laboratory staff.

Second, diversify supply chains and consider regional manufacturing or final assembly to reduce exposure to trade-related disruptions. Building validated dual-source options for critical reagents and components will enhance operational resilience and support sustained testing capacity. Third, develop targeted engagement plans for key end users-academic centers for translational validation, hospital laboratories for operational fit, and reference laboratories for scale. These plans should include clinician education, interpretive reporting templates, and collaborative pilot programs that demonstrate clinical value.

Fourth, pursue partnerships to expand multiplexing capabilities and to develop integrated diagnostic algorithms that combine serologic results with clinical decision support. Finally, incorporate patient-centric sampling approaches, such as dried blood spot programs, to broaden access and to support decentralized testing initiatives. By implementing these recommendations, stakeholders can strengthen their competitive positioning while delivering diagnostics that align with evolving clinical workflows and patient care models.

A transparent, multi-source research methodology combining expert interviews, guideline synthesis, and reproducible analytical frameworks to generate actionable diagnostic insights

This research synthesizes multiple data sources, structured interviews, and a transparent analytical framework to ensure robust, reproducible findings. Primary qualitative inputs include interviews with clinical laboratory directors, assay developers, regulatory affairs specialists, and clinicians who treat autoimmune diseases, providing practical insights into validation practices, adoption barriers, and clinical decision drivers. These interviews informed thematic analysis and guided the selection of case studies that illustrate real-world integration of assays into diagnostic pathways.

Secondary inputs comprised peer-reviewed literature, clinical practice guidelines, and regulatory documentation that clarify analytic requirements and evidence expectations for both in vitro diagnostics and lab-developed tests. The methodological approach balanced depth and breadth by triangulating qualitative inputs with technical performance characteristics reported in the literature, paying particular attention to assay-specific validation metrics and sample type considerations. Data synthesis emphasized reproducibility, with cross-validation steps to reconcile discrepancies across sources and to ensure that interpretive claims reflect consensus where possible.

Analytical techniques included comparative validation mapping across technologies and test types, scenario-based supply chain impact assessment, and segmentation-driven insight generation to highlight actionable priorities for developers and laboratories. Throughout, we maintained clear documentation of assumptions and methodological choices, enabling clients to evaluate the applicability of findings to specific programs or geographies.

Concluding perspective on aligning innovation, evidence generation, and operational resilience to drive meaningful improvements in autoimmune disease diagnosis

In closing, the autoimmune diagnostics field stands at an inflection point characterized by higher expectations for analytical performance, tighter alignment between evidence generation and clinical utility, and greater operational scrutiny driven by supply chain realities. Stakeholders who integrate rigorous validation, seamless workflow compatibility, and resilient procurement strategies will be best positioned to translate technological advances into tangible clinical impact. The interplay of in vitro diagnostics and lab-developed tests offers a pragmatic dual-pathway where standardization and agility coexist to meet diverse clinical needs.

Leaders should focus on generating the right kinds of evidence to satisfy clinicians and payers, while investing in interoperability and interpretive reporting to enhance clinical utility. At the same time, supply chain diversification and regional capacity planning will remain critical to ensuring continuity of testing services. Taken together, these priorities suggest a roadmap where innovation, evidence, and operations align to support earlier and more accurate diagnosis, improved patient management, and more efficient laboratory workflows. Stakeholders who act decisively to address these areas will drive adoption and deliver value to clinicians, patients, and healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. IVD & LDT For Autoimmune Diseases Market, by Test Type

  • 8.1. Anti Cyclic Citrullinated Peptide
  • 8.2. Antinuclear Antibody
  • 8.3. Celiac Disease
  • 8.4. Rheumatoid Factor

9. IVD & LDT For Autoimmune Diseases Market, by Technology

  • 9.1. Chemiluminescence Immunoassay
  • 9.2. Enzyme Linked Immunosorbent Assay
  • 9.3. Fluorescence Immunoassay
  • 9.4. Multiplex Immunoassay

10. IVD & LDT For Autoimmune Diseases Market, by Product Type

  • 10.1. In Vitro Diagnostic
  • 10.2. Lab Developed Test

11. IVD & LDT For Autoimmune Diseases Market, by Sample Type

  • 11.1. Dried Blood Spot
  • 11.2. Plasma
  • 11.3. Serum
  • 11.4. Whole Blood

12. IVD & LDT For Autoimmune Diseases Market, by End User

  • 12.1. Academic And Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospital Laboratories
  • 12.4. Reference Laboratories

13. IVD & LDT For Autoimmune Diseases Market, by Application

  • 13.1. Celiac Disease
  • 13.2. Multiple Sclerosis
  • 13.3. Rheumatoid Arthritis
  • 13.4. Systemic Lupus Erythematosus
  • 13.5. Type 1 Diabetes

14. IVD & LDT For Autoimmune Diseases Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. IVD & LDT For Autoimmune Diseases Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. IVD & LDT For Autoimmune Diseases Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States IVD & LDT For Autoimmune Diseases Market

18. China IVD & LDT For Autoimmune Diseases Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Adaptive Biotechnologies Corporation
  • 19.7. Agilent Technologies Inc.
  • 19.8. Atlas Link Technology Co., Ltd
  • 19.9. Becton, Dickinson and Company
  • 19.10. Bio-Rad Laboratories Inc.
  • 19.11. bioMerieux SA
  • 19.12. Corgenix, Inc.
  • 19.13. Danaher Corporation
  • 19.14. DiaSorin S.p.A.
  • 19.15. EUROIMMUN AG
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. Grifols, S.A.
  • 19.18. Hologic Inc.
  • 19.19. ImmunoScience India Pvt. Ltd.
  • 19.20. Ortho Clinical Diagnostics, Inc.
  • 19.21. PerkinElmer, Inc.
  • 19.22. Quest Diagnostics, Inc.
  • 19.23. Quidel Corporation
  • 19.24. Siemens Healthineers AG
  • 19.25. Sysmex Corporation
  • 19.26. Thermo Fisher Scientific Inc.
  • 19.27. Trinity Biotech plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTI CYCLIC CITRULLINATED PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY LAB DEVELOPED TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DRIED BLOOD SPOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY CELIAC DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)